Former Senator Ben Sasse recently spotlighted Revolution Medicines' upcoming Phase 3 trial results for a new pancreatic cancer pill. This high-profile endorsement brings broader market attention to biotech companies developing innovative therapies for historically untreatable, RAS-dependent solid tumors.
Published on April 12
These companies are working on treatments for cancers that have had almost no effective options for decades. If key Phase 3 trials succeed, the ripple effect across the entire sector could be enormous.
High-profile endorsements and growing institutional interest are shining a spotlight on this space right now. When professional investors and public figures start talking about a sector, it tends to move fast.
With major trial results on the horizon and regulatory momentum building, this thematic group is at an early but potentially pivotal inflection point. Getting in before the results land could make all the difference.
Former Senator Ben Sasse's spotlight on Revolution Medicines' Phase 3 trial for daraxonrasib — a daily pill targeting pancreatic cancer — has drawn fresh attention to the precision oncology space. These stocks are centred on a powerful idea: that some of the most aggressive, historically untreatable cancers, driven by complex genetic mutations known as RAS, may finally be within reach of targeted treatment. A clinical breakthrough here could shift the entire oncology sector.
This is a high-risk, high-reward thematic group. The companies included are mostly clinical-stage, meaning they are still running trials and have not yet brought products to market at scale. That means greater potential upside if trials succeed, but also real risk if they don't. This basket is best suited for investors who understand the speculative nature of early-stage biotech and are comfortable with volatility in exchange for exposure to potentially transformative milestones.
Every stock in this group was handpicked by professional analysts for its direct connection to RAS-mutation-targeted therapies or precision oncology diagnostics. From small molecule inhibitors and RNA-interference treatments to radiopharmaceuticals and live-cell encapsulation, each company is pursuing a unique angle on the same unmet medical need. These are not random picks — they represent a carefully considered cross-section of the most relevant players in this emerging field.
This basket's total market capitalisation is $26.59B and it is heavily anchored by large-cap constituents. The largest constituent represents the majority of capitalisation, so the basket's behaviour is likely to reflect large-cap stability rather than small-cap volatility.
RVMD: $19.11B
ERAS: $5.29B
CRDF: $108.02M
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+2
Here are a few of the assets in this group. Create an account to unlock the full list.
On average, analysts expect assets in this group to grow 294.06% over the next year.
11 of 12 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+294.06%
